- Home
- BUSE vs CGON Comparison
BUSE vs CGON Comparison
Compare BUSE & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- CGON
- Stock Information
- Founded
- BUSE 1868
- CGON 2010
- Country
- BUSE United States
- CGON United States
- Employees
- BUSE N/A
- CGON N/A
- Industry
- BUSE Major Banks
- CGON
- Sector
- BUSE Finance
- CGON
- Exchange
- BUSE Nasdaq
- CGON NYSE
- Market Cap
- BUSE 1.4B
- CGON 1.3B
- IPO Year
- BUSE N/A
- CGON 2024
- Fundamental
- Price
- BUSE $20.82
- CGON $20.61
- Analyst Decision
- BUSE Buy
- CGON Strong Buy
- Analyst Count
- BUSE 5
- CGON 10
- Target Price
- BUSE $27.80
- CGON $65.11
- AVG Volume (30 Days)
- BUSE 720.4K
- CGON 1.4M
- Earning Date
- BUSE 04-22-2025
- CGON 05-08-2025
- Dividend Yield
- BUSE 4.72%
- CGON N/A
- EPS Growth
- BUSE N/A
- CGON N/A
- EPS
- BUSE 1.98
- CGON N/A
- Revenue
- BUSE $453,703,000.00
- CGON $1,139,000.00
- Revenue This Year
- BUSE $65.20
- CGON N/A
- Revenue Next Year
- BUSE $12.01
- CGON $16,237.24
- P/E Ratio
- BUSE $10.71
- CGON N/A
- Revenue Growth
- BUSE 3.25
- CGON 461.08
- 52 Week Low
- BUSE $18.40
- CGON $14.80
- 52 Week High
- BUSE $28.97
- CGON $46.99
- Technical
- Relative Strength Index (RSI)
- BUSE 49.67
- CGON 44.94
- Support Level
- BUSE $19.55
- CGON $19.91
- Resistance Level
- BUSE $21.76
- CGON $21.60
- Average True Range (ATR)
- BUSE 0.90
- CGON 1.72
- MACD
- BUSE 0.22
- CGON 0.44
- Stochastic Oscillator
- BUSE 71.73
- CGON 88.32
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.